We use cookies essential for this site to function well. Please click "Accept" to help us improve its usefulness with additional cookies. Learn about our use of cookies, and collaboration with select social media and trusted analytics partners here.

Accept Use minimal essential cookies

Coronavirus vaccines progress: What’s next?

The rapid development of the COVID-19 vaccines is having a profound effect on the world. This collection takes a closer look at the development, rollout and future of vaccines.

FEATURED INSIGHTS

Webcast

COVID-19 vaccines are here. What does that mean for your organization?
– The COVID-19 vaccines have arrived but pressing questions remain on development, implications for the new strains, rollout challenges and the role companies can play in the worldwide vaccination effort.
Article

The risks and challenges of the global COVID-19-vaccine rollout
– A realistic assessment of the heroic effort to administer billions of doses of COVID-19 vaccines to an agonized global population is necessary—the stakes could not be higher.
Article

When will the COVID-19 pandemic end?
– This article updates our earlier perspectives on when the coronavirus pandemic will end. Transition toward normalcy in the United States remains most likely in the second quarter of 2021 and herd immunity in the third and fourth quarters, but the emergence of new strains and a slow start to vaccine rollout raise real risks to both timelines. We also add a perspective for the United Kingdom.

VACCINES AND THERAPEUTICS DEVELOPMENT

Article

On pins and needles: Tracking COVID-19 vaccines and therapeutics
– Key stakeholders will need to continue to monitor and adapt to new data and new variants emerging across the globe to respond effectively.
Article

Why tech transfer may be critical to beating COVID-19
– How quickly COVID-19 vaccine production ramps up will depend on technology transfer—the capabilities and processes that can speed vaccines from development to manufacturing. Are we ready?
Article

Refueling the innovation engine in vaccines
– Vaccine development has slowed over the past five years, but changes to investment strategies and a shift in focus to more technical and complex vaccines could renew the innovation engine.

VACCINE ROLLOUT & IMMUNIZATION

Article

“Getting shots into arms”: How US states are addressing the vaccine distribution challenge
– COVID-19 vaccine administration represents a significant challenge: States can accelerate progress through five lessons including establishing, enabling, and managing administration capacity.
Article

Is the world up to the challenge of mass COVID-19 vaccination?
– Amid the unforeseen effects of the pandemic on at-risk and lower-income communities, governments and organizations around the world must convene to ensure effective distribution of newly developed vaccines.
Article

COVID-19 vaccines meet 100 million uncertain Americans
– More than 100 million Americans are uncertain about vaccination. Public- and private-sector leaders can take action to support adoption, including incremental investment in the range of $10 billion.
Article

COVID-19 vaccine: Are US consumers ready?
– While details of COVID-19 vaccine administration are still pending, healthcare stakeholders may want to consider their long-term plans for consumer engagement in immunization. Here, we discuss the latest insights on US consumers’ reported acceptance of COVID-19 vaccination and considerations for healthcare leaders.
Article

The COVID-19 vaccines are here: What comes next?
– Countries must prepare now for the largest simultaneous global public-health initiative ever undertaken.
Interactive

How Americans feel about COVID-19 vaccinations
Over half the respondents in the United States report an interest in taking a COVID-19 vaccine though safety and efficacy concerns remain drivers for vaccine hesitancy.